Abstracts tagged "Biologics and polychondritis"

Abstract Number: 1329 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Biologics in Relapsing Polychondritis: A National Multicenter Study in France
Guillaume Moulis^1,2,3, Grégory Pugnet⁴, Nathalie Costedoat-Chalumeau⁵, Alexis Mathian⁶, Gaëlle Leroux⁷, Jonathan Boutemy⁸, Laurence Bouillet⁹, Sabine Berthier¹⁰, Jean Baptiste Gaultier¹¹, Pierre-Yves Jeandel¹², Amadou Konaté¹³, Arsène Mékinian¹⁴, Elisabeth Solau-Gervais¹⁵, Benjamin Terrier^16,17, Daniel Wendling¹⁸, Camille Garnier¹, Pascal Cathebras¹⁹, Laurent Arnaud²⁰, Patrice Cacoub⁷, Zahir Amoura⁶, Jean-Charles Piette⁷, Philippe Arlet²¹, Aurore Palmaro², Maryse Lapeyre-Mestre² and Laurent Sailler²², ¹Internal Medicine, Toulouse University Hospital, Toulouse, France, ²UMR 1027, INSERM-University of Toulouse, Toulouse, France, ³CIC 1436, Toiulouse, France, ⁴Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁵Cochin University Hospital, Internal Medicine, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁸Department of Internal Medicine, Caen University Hospital, Caen, France, ⁹CHU, Grenoble, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹¹Internal medicine, Saint Etienne, France, ¹²Internal Medicine, Nice University Hospital, Nice, France, ¹³Internal Medicine, Montpellier University Hospital, Montpellier, France, ¹⁴Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ¹⁵Rheumatology Department, University Hospital, Poitiers, Poitiers, France, ¹⁶INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ¹⁸Service de Rhumatologie, CHU Jean Minjoz, Besancon, France, ¹⁹Internal Medicine, University Hospital St Etienne, St Etienne, France, ²⁰Inserm UMRS 1136, Paris, France, ²¹Service de Médecine Interne, CHU Purpan, Toulouse,, France, ²²Internal Medicine, Internal Medicine department, Toulouse University Hospital, Toulouse, France
Background/Purpose: No study has compared the efficacy and the safety of biologics in a large relapsing polychondritis (RP) cohort. This is the aim of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].